PATIENT ALERT: Information regarding COVID-19. 

Clinical Research & Trials

USO 19241

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) (D9670C00001)


Disease Types: Breast Cancer Research

Eligibility Requirements:

-Advanced/metastatic HER 2 low or negative, HR (hormone receptor) positive breast cancer 
-Must have progressed on and after last treatment, had 2 previous lines of endocrine therapy and progressed, measurable disease
-No: prior chemotherapy for advanced or metastatic breast cancer; MI (myocardial infarction) within last 6 months, interstitial lung disease or pneumonitis; clinically significant pulmonary condition such as PE (pulmonary embolus) within 
Last 3 months, severe asthma, severe COPD, restrictive lung disease, pleural effusion; spinal cord compression or active CNS metastasis; known HIV or active Hep B or Hep C; previous treatment with anti-HER 2 therapy

Available at: